Multimodal Al for Precision Diagnosis of Esophageal Cancer
Reason given: local ethics review
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Zhongshan HospitalShanghai, ChinaNo longer taking part
Trial details
- Who runs it
- Shanghai Zhongshan Hospital
- Trial code
- NCT07629921
- Record updated
- 18 August 2026
- Original description
This study intends to construct two multimodal deep learning models: one for the diagnosis of esophageal cancer and the prediction of invasive depth to assess suitability for endoscopic resection; the other model, based on this, classifies endoscopic non-resectable patients into different degrees of invasion to further explore the differences in the sensitivity and survival of AI-predicted benign and malignant tumors in patients' responses to NAT, thereby providing reliable decision support for precise individualized treatment. This aspect has rarely been addressed in previous studies.Read full original descriptionShow less
This study intends to construct two multimodal deep learning models: one for the diagnosis of esophageal cancer and the prediction of invasive depth to assess suitability for endoscopic resection; the other model, based on this, classifies endoscopic non-resectable patients into different degrees of invasion to further explore the differences in the sensitivity and survival of AI-predicted benign and malignant tumors in patients' responses to NAT, thereby providing reliable decision support for precise individualized treatment. This aspect has rarely been addressed in previous studies.
Inclusion: Age ≥18 years; Histologically confirmed or clinically suspected esophageal squamous cell carcinoma (ESCC); Availability of pre-treatment endoscopic images and contrast-enhanced chest/upper abdominal CT scans; Availability of complete clinical and pathological data; Patients who underwent endoscopic resection (ESD/EMR) or esophagectomy with pathological assessment of tumor invasion depth; Adequate image quality for analysis; Written informed consent (for prospective cohorts, if applicable).
Exclusion: Prior treatment for esophageal cancer before baseline imaging, including chemotherapy, radiotherapy, immunotherapy, or endoscopic resection; Distant metastatic disease at diagnosis; History of another active malignancy within the past 5 years; Recurrent esophageal cancer; Histology other than squamous cell carcinoma; Incomplete clinical, imaging, or pathological data; Poor-quality CT or endoscopic images unsuitable for analysis.